Descriptive Analysis of Changes in Hepatitis B Markers in People Living With HIV on Injectable Therapy.

N/ANot Yet RecruitingNCT06421259

Centre Hospitalier Universitaire de Nice15 enrolled

Overview

In order to assess the risk of hepatitis B reactivation in people living with HIV and undergoing injection therapy, we propose to carry out a descriptive analysis of the evolution of hepatitis B markers in this population.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hiv Infection Hepatitis B

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: -HIV infected patients under injectable ART Exclusion Criteria: -Active HBV infection

Locations (1)

CHU NiICE

Nice, Alpes Maritimes, France

Outcomes

Primary Outcomes

Risk of HBV reactivation under injectable HIV ART

HBV serology, DNA HBV levels

Time frame: From start of injectable HIV treatment to hepatitis B reactivation, assessed up to 24 months

Central Contacts

Alissa NAQVI

CONTACT

492035468 naqvi.a@chu-nice.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.